JOHNSON & JOHNSON will acquire biotech Firefly Bio for $1 billion in cash to expand its oncology pipeline. The deal centers on Firefly's Firelink platform, which targets KRAS-mutated solid tumors previously considered undruggable. This acquisition bolsters J&J’s capacity to treat high-unmet-need cancers, potentially extending survival rates currently measured in months.

Targeting the "Undruggable" KRAS Mutation